Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9684294 | 0.88 | CYP2D6 (0.49) | CHRM2CHRM1MEN1KMT2ACYP2D6 | |
| SCHEMBL3659567 | 0.78 | BCHE (0.45) | MEN1KMT2AALDH1A1 | |
| SCHEMBL977897 | 0.77 | CYP3A4 (0.42) | CHRM2CHRM1CYP2D6ALDH1A1 | |
| SCHEMBL11459022 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL70441 | 0.73 | CYP2D6 (0.46) | CHRM2CHRM1MEN1KMT2AHTR2A | |
| SCHEMBL24238281 | 0.73 | OPRM1 (0.42) | CHRM2CHRM1MEN1KMT2AHTR2A | |
| SCHEMBL24238344 | 0.73 | OPRM1 (0.42) | CHRM2CHRM1MEN1KMT2AHTR2A | |
| SCHEMBL17621817 | 0.71 | CYP2D6 (0.38) | CHRM2CHRM1MEN1KMT2ACYP2D6 | |
| SCHEMBL24238345 | 0.70 | CYP2D6 (0.40) | CHRM2CHRM1MEN1KMT2AHTR2A | |
| SCHEMBL11468789 | 0.69 | PIM1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2215077-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | GPR119, GIPR, GPR39 | MCOLN3 1095/4885CHRM2 473/4885CHRM1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.